Nance Lovelace
Family Medicine · New Market, VANPI 1447216163
Payments from drug & device makers
Across 205 payments — averaging $15.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$700
- AstraZeneca$510
- Pfizer$286
- Amgen$263
- Lilly USA, LLC$217
- Johnson & Johnson$209
- plus $997 from 20 others
What the payments were for
- Food & beverage$3,172100%
- Education$110%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 51 | $700 |
| AstraZeneca | 31 | $510 |
| Pfizer | 21 | $286 |
| Amgen | 16 | $263 |
| Lilly USA, LLC | 15 | $217 |
| Johnson & Johnson | 13 | $209 |
| Merck | 10 | $146 |
| Boehringer Ingelheim | 7 | $130 |
| Abbott | 5 | $127 |
| AbbVie | 8 | $118 |
| Currax Pharmaceuticals LLC | 4 | $61 |
| Novartis | 3 | $48 |
| E.r. Squibb & Sons, L.L.C. | 3 | $42 |
| Genentech USA, Inc. | 2 | $38 |
| GSK | 2 | $35 |
| Exact Sciences | 1 | $34 |
| Teva Pharmaceuticals USA, Inc. | 2 | $30 |
| Esperion Therapeutics, Inc. | 1 | $29 |
| Amarin Pharma, Inc. | 2 | $26 |
| Dexcom, Inc. | 1 | $25 |
| Astellas Pharma US Inc | 1 | $23 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $20 |
| Medtronic | 1 | $18 |
| Kowa Pharmaceuticals America, Inc. | 1 | $17 |
| Mylan Specialty L.p. | 1 | $15 |
| Otsuka America Pharmaceutical, Inc. | 1 | $14 |
How this compares
$3,183 in reported general payments places this provider in the 80th percentile of 2,553 family medicine providers in Virginia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 196 | $141,448 |
| OzempicSemaglutide | 70 | $94,099 |
| Tresiba Flextouch U-200Insulin Degludec | 32 | $54,515 |
| XareltoRivaroxaban | 58 | $48,530 |
| JardianceEmpagliflozin | 37 | $46,198 |
| JanuviaSitagliptin Phosphate | 46 | $41,959 |
| LinzessLinaclotide | 32 | $23,833 |
| FarxigaDapagliflozin Propanediol | 22 | $20,969 |
| Spiriva RespimatTiotropium Bromide | 35 | $19,011 |
| JanumetSitagliptin Phos/Metformin Hcl | 17 | $14,191 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 14 | $11,376 |
| Bydureon BciseExenatide Microspheres | 13 | $11,142 |
| SymbicortBudesonide/Formoterol Fumarate | 24 | $9,725 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 44 | $9,424 |
| MovantikNaloxegol Oxalate | 18 | $7,249 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $286 | $141,448196 claims |
| Novo NordiskOzempic | $700 | $94,09970 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat | $130 | $65,20972 claims |
| MerckJanuvia, Janumet | $146 | $56,15063 claims |
| Johnson & JohnsonXarelto | $209 | $48,53058 claims |
| AstraZenecaFarxiga, Symbicort | $510 | $30,69446 claims |
| AbbVieLinzess, Fetzima | $118 | $30,62046 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $35 | $18,07729 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,553 family medicine providers in Virginia.
Other family medicine in New Market
- Aaron HartmanMidlothian$17.4M
- John ScottGlen Allen$16.7M
- Banu MyneniPortsmouth$12.8M
- Patricia HouserWinchester$3.5M
- Stephan JannachDanville$3M
- Linda SchneiderHampton$2.1M
- Jennifer BrownMidlothian$1.3M
- Brian McCormickHampton$793K
- Jerome DanielNorth Chesterfield$779K
- Samir AbdelshaheedChesapeake$642K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.